EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

A Review of the Potential Utility of Mycophenolate Mofetil as a Cancer Therapeutic

Nazanin Majd, Kazutaka Sumita, Hirofumi Yoshino, Dillon Chen, Jumpei Terakawa, Takiko Daikoku, Satoshi Kofuji, Richard Curry, Trisha M. Wise-Draper, Ronald E. Warnick, Jessica Guarnaschelli, Atsuo T. Sasaki

Journal of Cancer Research · 2014

DOI: 10.1155/2014/423401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research, 2014. Verfasst von Nazanin Majd und 11 weiteren Autor:innen. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Mayfield Education Research Foundation Cincinnati, American Association of Neurological Surgeons, Uehara Memorial Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor cells adapt to their high metabolic state by increasing energy production. To this end, current efforts in molecular cancer therapeutics have been focused on signaling pathways that modulate cellular metabolism. However, targeting such signaling pathways is challenging due to heterogeneity of tumors and recurrent oncogenic mutations. A critical need remains to develop antitumor drugs that target tumor specific pathways. Here, we discuss an energy metabolic pathway that is preferentially activated in several cancers as a potential target for molecular cancer therapy. In vitro studies have revealed that many cancer cells synthesize guanosine triphosphate (GTP), via the de novo purine nucleotide synthesis pathway by upregulating the rate limiting enzyme of this pathway, inosine monophosphate dehydrogenase (IMPDH). Non-proliferating cells use an alternative purine nucleotide synthesis pathway, the salvage pathway, to synthesize GTP. These observations pose IMPDH as a potential target to suppress tumor cell growth. The IMPDH inhibitor, mycophenolate mofetil (MMF), is an FDA-approved immunosuppressive drug. Accumulating evidence shows that, in addition to its immunosuppressive effects, MMF also has antitumor effects via IMPDH inhibition in vitro and in vivo . Here, we review the literature on IMPDH as related to tumorigenesis and the use of MMF as a potential antitumor drug.

Förderung

  • Mayfield Education Research Foundation Cincinnati
  • American Association of Neurological Surgeons
  • Uehara Memorial Foundation
  • UC-Brain Tumor Center
  • Marlene Harris-Ride Cincinnati Foundation

Zitieren

APA

Majd, N., Sumita, K., Yoshino, H., Chen, D., Terakawa, J., Daikoku, T., Kofuji, S., Curry, R., Wise-Draper, T. M., Warnick, R. E., Guarnaschelli, J., & Sasaki, A. T. (2014). A Review of the Potential Utility of Mycophenolate Mofetil as a Cancer Therapeutic. Journal of Cancer Research. https://doi.org/10.1155/2014/423401

Vancouver

Majd N, Sumita K, Yoshino H, Chen D, Terakawa J, Daikoku T, et al. A Review of the Potential Utility of Mycophenolate Mofetil as a Cancer Therapeutic. Journal of Cancer Research. 2014. doi:10.1155/2014/423401

BibTeX
@article{Majd2014,
  author = {Majd, Nazanin and Sumita, Kazutaka and Yoshino, Hirofumi and Chen, Dillon and Terakawa, Jumpei and Daikoku, Takiko and Kofuji, Satoshi and Curry, Richard and Wise-Draper, Trisha M. and Warnick, Ronald E. and Guarnaschelli, Jessica and Sasaki, Atsuo T.},
  title = {A Review of the Potential Utility of Mycophenolate Mofetil as a Cancer Therapeutic},
  journal = {Journal of Cancer Research},
  year = {2014},
  doi = {10.1155/2014/423401}
}
Kostenlos starten →